title: Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy.
abstract: Chemotherapy-associated cardiotoxicity can present as a spectrum from arrhythmia to acute congestive heart failure. Unlike anthracyclines, proteasome inhibitors - for example, bortezomib - are not notorious for causing cardiotoxicity in absence of pre-existing cardiac dysfunction or without concomitant use of other cardiotoxic agents. We describe a 66-year-old woman with end-stage renal disease who developed acute dyspnea hours after a third treatment with bortezomib for IgG kappa myeloma. The Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) between bortezomib and acute left ventricular dysfunction. Patients receiving proteasome inhibitors should be closely monitored for evidence of cardiac dysfunction during treatment.
authors.affiliation: Department of Internal Medicine, The Guthrie Clinic, Sayre, PA, USA; marcellegeorge2000@hotmail.com.
authors.forename: Marcelle G
authors.initials: MG
authors.lastname: Meseeha
authors.affiliation: Department of Internal Medicine, The Guthrie Clinic, Sayre, PA, USA.
authors.forename: Victor O
authors.initials: VO
authors.lastname: Kolade
authors.affiliation: Department of Family Medicine, The Guthrie Clinic, Sayre, PA, USA.
authors.forename: Maximos N
authors.initials: MN
authors.lastname: Attia
keywords: bortezomib; cardiotoxicity; heart failure; multiple myeloma; proteasome inhibitors